{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:43Z","timestamp":1791924223912,"version":"4.3.4"},"reference-count":172,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1053\/j.ackd.2021.08.001","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T12:04:15Z","timestamp":1645185855000},"page":"402-414.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Conventional Chemotherapy Nephrotoxicity"],"prefix":"10.1053","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5747-2151","authenticated-orcid":false,"given":"Shruti","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Portales-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Daher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4340-5046","authenticated-orcid":false,"given":"Abhijat","family":"Kitchlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ejim.2011.05.005","article-title":"Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study","volume":"22","author":"Christiansen","year":"2011","journal-title":"Eur J Intern Med"},{"issue":"10","key":"10.1053\/j.ackd.2021.08.001_bib2","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.03140312","article-title":"Onco-nephrology: AKI in the cancer patient","volume":"7","author":"Lam","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ackd.2021.08.001_bib3","first-page":"351","article-title":"Acute kidney injury in patients with cancer","volume":"32","author":"Perazella","year":"2018","journal-title":"Oncology (Williston Park)"},{"issue":"10","key":"10.1053\/j.ackd.2021.08.001_bib4","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2215\/CJN.02780312","article-title":"Onco-nephrology: renal toxicities of chemotherapeutic agents","volume":"7","author":"Perazella","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ackd.2021.08.001_bib5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nrneph.2009.97","article-title":"Chemotherapy-associated renal dysfunction","volume":"5","author":"Sahni","year":"2009","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib6","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1470-2045(19)30145-7","article-title":"Dose recommendations for anticancer drugs in patients with renal or hepatic impairment","volume":"20","author":"Krens","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1053\/j.ackd.2021.08.001_bib7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1053\/j.ackd.2021.08.001_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41585-020-00404-6","article-title":"Defining cisplatin eligibility in patients with muscle-invasive bladder cancer","volume":"18","author":"Jiang","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"8","key":"10.1053\/j.ackd.2021.08.001_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11864-020-00767-3","article-title":"New treatment options for advanced Biliary Tract cancer","volume":"21","author":"Mizrahi","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"19","key":"10.1053\/j.ackd.2021.08.001_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/chin.200319278","article-title":"Biochemical Modulation of cisplatin mechanisms of action: Enhancement of antitumor activity and Circumvention of drug resistance","volume":"34","author":"Fuertes","year":"2003","journal-title":"ChemInform"},{"issue":"22","key":"10.1053\/j.ackd.2021.08.001_bib11","doi-asserted-by":"crossref","first-page":"14298","DOI":"10.1073\/pnas.162491399","article-title":"Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals","volume":"99","author":"Ishida","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib12","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/clpt.2009.139","article-title":"Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity","volume":"86","author":"Filipski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1053\/j.ackd.2021.08.001_bib13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/0006-2952(74)90354-2","article-title":"Interactions between mammalian cell DNA and inorganic platinum compounds-I. DNA interstrand cross-linking and cytotoxic properties of platinum(II) compounds","volume":"23","author":"Pascoe","year":"1974","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","article-title":"Cellular processing of platinum anticancer drugs","volume":"4","author":"Wang","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1053\/j.ackd.2021.08.001_bib15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.ki.5002786","article-title":"Cisplatin nephrotoxicity: mechanisms and renoprotective strategies","volume":"73","author":"Pabla","year":"2008","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ackd.2021.08.001_bib16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0270-9295(03)00089-5","article-title":"Cisplatin nephrotoxicity","volume":"23","author":"Arany","year":"2003","journal-title":"Semin Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0305-7372(98)90061-5","article-title":"Cumulative toxicities from cisplatin therapy and current cytoprotective measures","volume":"24","author":"Cvitkovic","year":"1998","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1053\/j.ackd.2021.08.001_bib18","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3390\/cancers13071572","article-title":"Mechanisms of cisplatin-induced acute kidney Injury","volume":"13","author":"Mechanisms","year":"2021","journal-title":"Cancers"},{"key":"10.1053\/j.ackd.2021.08.001_bib19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1053\/j.ackd.2021.08.001_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000168693","article-title":"Long-term renal effect of cisplatin in man","volume":"14","author":"Brillet","year":"1994","journal-title":"Am J Nephrol"},{"issue":"8","key":"10.1053\/j.ackd.2021.08.001_bib21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/SMJ.0b013e3181e63682","article-title":"Cisplatin-induced renal salt wasting syndrome","volume":"103","author":"Hamdi","year":"2010","journal-title":"South Med J"},{"issue":"3","key":"10.1053\/j.ackd.2021.08.001_bib22","first-page":"439","article-title":"Thrombotic microangiopathy following chemotherapy with S-1 and cisplatin in a patient with gastric cancer: a case report","volume":"31","author":"Muto","year":"2017","journal-title":"In\u00a0Vivo (Brooklyn)"},{"key":"10.1053\/j.ackd.2021.08.001_bib23","first-page":"160","article-title":"Cancer Chemotherapy and Pharmacology","volume":"127","author":"International","year":"1985","journal-title":"Growth (Lakeland)"},{"issue":"7","key":"10.1053\/j.ackd.2021.08.001_bib24","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.08070715","article-title":"Long-term renal outcomes after cisplatin treatment","volume":"11","author":"Latcha","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"17","key":"10.1053\/j.ackd.2021.08.001_bib25","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2001.19.17.3733","article-title":"Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure","volume":"19","author":"De Jongh","year":"2001","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.ackd.2021.08.001_bib26","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/sj.bjc.6600884","article-title":"Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients","volume":"88","author":"De Jongh","year":"2003","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1053\/j.ackd.2021.08.001_bib27","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10157-009-0215-1","article-title":"Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats","volume":"13","author":"Yokoo","year":"2009","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2021.08.001_bib28","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","article-title":"A systematic review of strategies to prevent cisplatin-induced nephrotoxicity","volume":"22","author":"Crona","year":"2017","journal-title":"Oncologist"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2050-6511-15-70","article-title":"Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study","volume":"15","author":"Oka","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/jjco\/hyu004","article-title":"Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study","volume":"44","author":"Yoshida","year":"2014","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib31","first-page":"2199","article-title":"Nephroprotective effects of hydration with magnesium in patients with cervical cancer receiving cisplatin","volume":"35","author":"Yamamoto","year":"2015","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1053\/j.ackd.2021.08.001_bib32","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2353\/ajpath.2010.090610","article-title":"Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions","volume":"176","author":"Ciarimboli","year":"2010","journal-title":"Am J Pathol"},{"issue":"11","key":"10.1053\/j.ackd.2021.08.001_bib33","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins (Basel)"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00228-019-02771-5","article-title":"Systematic review and meta-analysis of the efficacy of clinically tested protectants of cisplatin nephrotoxicity","volume":"76","author":"Casanova","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"issue":"14","key":"10.1053\/j.ackd.2021.08.001_bib35","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s40265-019-01182-1","article-title":"Prevention of cisplatin-induced acute kidney injury: a systematic review and meta-analysis","volume":"79","author":"Hamroun","year":"2019","journal-title":"Drugs"},{"issue":"11","key":"10.1053\/j.ackd.2021.08.001_bib36","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1248\/bpb.33.1867","article-title":"Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity","volume":"33","author":"Katsuda","year":"2010","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"10.1053\/j.ackd.2021.08.001_bib37","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/S0002-9440(10)61234-5","article-title":"Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2","volume":"167","author":"Ciarimboli","year":"2005","journal-title":"Am J Pathol"},{"issue":"1-2","key":"10.1053\/j.ackd.2021.08.001_bib38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cbi.2010.10.014","article-title":"Carvedilol protects against cisplatin-induced oxidative stress, redox state unbalance and apoptosis in rat kidney mitochondria","volume":"189","author":"Rodrigues","year":"2011","journal-title":"Chem Biol Interact"},{"issue":"6","key":"10.1053\/j.ackd.2021.08.001_bib39","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ki.2012.199","article-title":"Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats","volume":"82","author":"Humanes","year":"2012","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ackd.2021.08.001_bib40","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1093\/ndt\/gfl194","article-title":"Rosiglitazone ameliorates cisplatin-induced renal injury in mice","volume":"21","author":"Lee","year":"2006","journal-title":"Nephrol Dial Transpl"},{"key":"10.1053\/j.ackd.2021.08.001_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-9-107","article-title":"Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats","volume":"9","author":"Tikoo","year":"2009","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib42","doi-asserted-by":"crossref","first-page":"F1041","DOI":"10.1152\/ajprenal.00512.2019","article-title":"Canagliflozin reduces cisplatin uptake and activates Akt to protect against cisplatin-induced nephrotoxicity","volume":"318","author":"Song","year":"2020","journal-title":"Am J Physiol - Ren Physiol"},{"issue":"3","key":"10.1053\/j.ackd.2021.08.001_bib43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/BF00257742","article-title":"Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II","volume":"9","author":"Calvert","year":"1982","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1053\/j.ackd.2021.08.001_bib44","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2165\/00003495-198937020-00005","article-title":"Carboplatin: a Preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer","volume":"37","author":"Wagstaff","year":"1989","journal-title":"Drugs"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib45","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2165\/00003088-199121040-00002","article-title":"Clinical pharmacokinetics of carboplatin","volume":"21","author":"van der Vijgh","year":"1991","journal-title":"Clin Pharmacokinet"},{"issue":"15_suppl","key":"10.1053\/j.ackd.2021.08.001_bib46","doi-asserted-by":"crossref","first-page":"6036","DOI":"10.1200\/jco.2015.33.15_suppl.6036","article-title":"A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN)","volume":"33","author":"Li","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ackd.2021.08.001_bib47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.critrevonc.2016.03.014","article-title":"Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies","volume":"102","author":"Ho","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib48","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.critrevonc.2006.02.003","article-title":"The development of platinum compounds and their possible combination","volume":"60","author":"Pasetto","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"10.1053\/j.ackd.2021.08.001_bib49","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/0020-711X(94)90072-8","article-title":"A comparison of in\u00a0vitro platinum-DNA adduct formation between carboplatin and cisplatin","volume":"26","author":"Atsushi","year":"1994","journal-title":"Int J Biochem"},{"issue":"2","key":"10.1053\/j.ackd.2021.08.001_bib50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/1389557024605500","article-title":"Biomolecular targets for platinum antitumor drugs","volume":"2","author":"Bose","year":"2005","journal-title":"Mini-reviews Med Chem"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib51","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.1999.17.1.409","article-title":"Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin","volume":"17","author":"Go","year":"1999","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.ackd.2021.08.001_bib52","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ackd.2021.08.001_bib53","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ctrv.2018.07.002","article-title":"Impact of aging on the risk of platinum-related renal toxicity: a systematic review and meta-analysis","volume":"69","author":"Duan","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1053\/j.ackd.2021.08.001_bib54","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/sj.bjc.6690697","article-title":"Dose-related nephrotoxicity of carboplatin in children","volume":"81","author":"English","year":"1999","journal-title":"Br J Cancer"},{"issue":"18","key":"10.1053\/j.ackd.2021.08.001_bib55","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1016\/j.ejca.2009.06.032","article-title":"Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors","volume":"45","author":"Skinner","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib56","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/bjc.1989.233","article-title":"Acute and cumulative effects of carboplatin on renal function","volume":"60","author":"Sleijfer","year":"1989","journal-title":"Br J Cancer"},{"issue":"September 2019","key":"10.1053\/j.ackd.2021.08.001_bib57","first-page":"1","article-title":"Carboplatin and hypomagnesemia: is it really a problem?","author":"Gaughran","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib58","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0272-6386(99)70114-9","article-title":"Deletions in the mitochondrial DNA and decrease in the oxidative phosphorylation activity of children with Fanconi syndrome secondary to antiblastic therapy","volume":"34","author":"Di Cataldo","year":"1999","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ackd.2021.08.001_bib59","doi-asserted-by":"crossref","first-page":"384","DOI":"10.5414\/CNP58384","article-title":"Renal failure due to scleroderma with thrombotic microangiopathy developing in a woman treated with carboplatin for ovarian cancer","volume":"58","author":"Karim","year":"2002","journal-title":"Clin Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2021.08.001_bib60","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/gyno.1993.1184","article-title":"Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin","volume":"50","author":"Cornelison","year":"1993","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1053\/j.ackd.2021.08.001_bib61","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1517\/14656566.4.6.889","article-title":"Toxicity of platinum compounds","volume":"4","author":"Hartmann","year":"2003","journal-title":"Expert Opin Pharmacother"},{"issue":"5 Suppl 15","key":"10.1053\/j.ackd.2021.08.001_bib62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/sonc.2002.35524","article-title":"Oxaliplatin-related side effects: Characteristics and management","volume":"29","author":"Cassidy","year":"2002","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib63","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2165\/00003495-200060040-00005","article-title":"Oxaliplatin: a review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies","volume":"60","author":"Culy","year":"2000","journal-title":"Drugs"},{"issue":"11","key":"10.1053\/j.ackd.2021.08.001_bib64","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1007\/PL00012514","article-title":"Cellular and molecular aspects of drugs of the future: Oxaliplatin","volume":"59","author":"Di Francesco","year":"2002","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"10.1053\/j.ackd.2021.08.001_bib65","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1124\/mol.54.5.770","article-title":"Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA","volume":"54","author":"Woynarowski","year":"1998","journal-title":"Mol Pharmacol"},{"issue":"10","key":"10.1053\/j.ackd.2021.08.001_bib66","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1023\/A:1008213732429","article-title":"Oxaliplatin: a review of preclinical and clinical studies","volume":"9","author":"Raymond","year":"1998","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1053\/j.ackd.2021.08.001_bib67","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1200\/JCO.2003.11.015","article-title":"Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute organ dysfunction working group study","volume":"21","author":"Takimoto","year":"2003","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib68","first-page":"1205","article-title":"Clinical pharmacokinetics of oxaliplatin: a critical review","volume":"6","author":"Graham","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1053\/j.ackd.2021.08.001_bib69","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/ndt\/gfh826","article-title":"Renal toxicity of oxaliplatin [6]","volume":"20","author":"Labaye","year":"2005","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib70","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/ckj\/sft148","article-title":"Severe acute tubular necrosis observed subsequent to oxaliplatin administration","volume":"7","author":"Filewod","year":"2014","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1053\/j.ackd.2021.08.001_bib71","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s13730-019-00390-8","article-title":"A case of biopsy-proven oxaliplatin-induced acute tubulointerstitial nephritis with thrombocytopenia and anemia","volume":"8","author":"Yamada","year":"2019","journal-title":"CEN case Rep"},{"issue":"8","key":"10.1053\/j.ackd.2021.08.001_bib72","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/CAD.0b013e3280e9496d","article-title":"Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature","volume":"18","author":"Cobo","year":"2007","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1053\/j.ackd.2021.08.001_bib73","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/CAD.0b013e3280102f4b","article-title":"Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report","volume":"18","author":"Buti","year":"2007","journal-title":"Anticancer Drugs"},{"issue":"2","key":"10.1053\/j.ackd.2021.08.001_bib74","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5414\/CN109131","article-title":"Oxaliplatin-induced acute tubulointerstitial nephritis: two case reports","volume":"89","author":"Choi","year":"2018","journal-title":"Clin Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib75","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3109\/02841860903464015","article-title":"An association between transient hypokalemia and severe acute oxaliplatin-related toxicity predominantly in women","volume":"49","author":"Chay","year":"2010","journal-title":"Acta Oncol (Madr)"},{"key":"10.1053\/j.ackd.2021.08.001_bib76","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1752-1947-4-36","article-title":"Transient bilateral abducens neuropathy with post-tetanic facilitation and acute hypokalemia associated with oxaliplatin: a case report","volume":"4","author":"Tan","year":"2010","journal-title":"J Med Case Rep"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib77","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2133\/dmpk.DMPK-13-RV-119","article-title":"Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy","volume":"29","author":"Inoue","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib78","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.1997.15.1.76","article-title":"Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children\u2019s Cancer Group","volume":"15","author":"Provisor","year":"1997","journal-title":"J Clin Oncol"},{"issue":"6264","key":"10.1053\/j.ackd.2021.08.001_bib79","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.282.6264.600","article-title":"Methotrexate treatment of squamous-cell head and neck cancers: dose-response evaluation","volume":"282","author":"Woods","year":"1981","journal-title":"Br Med J (Clin Res Ed"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib80","first-page":"874","article-title":"Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children\u2019s Oncology Group (POG 9404)","volume":"118","author":"Asselin","year":"2011","journal-title":"Blood J Am Soc Hematol"},{"key":"10.1053\/j.ackd.2021.08.001_bib81","first-page":"125","article-title":"Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin\u2019s lymphoma of unfavorable histology","volume":"65","author":"Canellos","year":"1981","journal-title":"Cancer Treat Rep"},{"issue":"5","key":"10.1053\/j.ackd.2021.08.001_bib82","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"issue":"27","key":"10.1053\/j.ackd.2021.08.001_bib83","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1056\/NEJMc1507547","article-title":"Acute methotrexate-induced crystal nephropathy","volume":"373","author":"Garneau","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ackd.2021.08.001_bib84","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ki.2011.97","article-title":"Methotrexate in the urine","volume":"80","author":"Mallipattu","year":"2011","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib85","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0002-9343(99)00041-8","article-title":"Crystal-induced acute renal failure","volume":"106","author":"Perazella","year":"1999","journal-title":"Am J Med"},{"issue":"7","key":"10.1053\/j.ackd.2021.08.001_bib86","first-page":"1389","article-title":"Changes in glomerular filtration rate associated with high-dose methotrexate therapy in adults","volume":"61","author":"Howell","year":"1977","journal-title":"Cancer Treatment Rep"},{"issue":"10","key":"10.1053\/j.ackd.2021.08.001_bib87","first-page":"2222","article-title":"High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma: incidence, treatment, and outcome","volume":"100","author":"Widemann","year":"2004","journal-title":"Cancer Interdiscip Int J Am Cancer Soc"},{"issue":"6","key":"10.1053\/j.ackd.2021.08.001_bib88","first-page":"348","article-title":"Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function","volume":"40","author":"Hempel","year":"2003","journal-title":"Med Pediatr Oncol Off J Siop\u2014international Soc Pediatr Oncol (Societ\u00e9 Int D\u2019oncologie P\u00e9diatrique"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib89","first-page":"745","article-title":"Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration","volume":"61","author":"Von Hoff","year":"1977","journal-title":"Cancer Treat Rep"},{"issue":"6","key":"10.1053\/j.ackd.2021.08.001_bib90","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3109\/10428194.2013.840780","article-title":"High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis","volume":"55","author":"May","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1053\/j.ackd.2021.08.001_bib91","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01213011-200505000-00002","article-title":"A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination","volume":"15","author":"Hulot","year":"2005","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"10.1053\/j.ackd.2021.08.001_bib92","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","article-title":"Understanding and managing methotrexate nephrotoxicity","volume":"11","author":"Widemann","year":"2006","journal-title":"Oncologist"},{"issue":"3","key":"10.1053\/j.ackd.2021.08.001_bib94","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ackd.2021.08.001_bib95","first-page":"1","article-title":"Incorporating cystatin C to Predict methotrexate elimination in patients with CNS lymphoma and Suspicious renal function","volume":"2018","author":"Barreto","year":"2018","journal-title":"Case Rep Hematol"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib96","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13318-012-0113-x","article-title":"Effect of ketoprofen and indomethacin on methotrexate pharmacokinetics in mice plasma and tumor tissues","volume":"38","author":"Elmorsi","year":"2013","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib97","first-page":"481","article-title":"Serious methotrexate toxicity caused by interaction with ibuprofen","volume":"11","author":"Cassano","year":"1989","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"2","key":"10.1053\/j.ackd.2021.08.001_bib98","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1124\/jpet.102.034330","article-title":"Characterization of methotrexate transport and its drug interactions with human organic anion transporters","volume":"302","author":"Takeda","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib99","first-page":"609","article-title":"Severe pancytopenia in a patient taking low dose methotrexate and probenecid","volume":"18","author":"Basin","year":"1991","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1053\/j.ackd.2021.08.001_bib100","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"issue":"25","key":"10.1053\/j.ackd.2021.08.001_bib101","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2009.25.4540","article-title":"Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome","volume":"28","author":"Widemann","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.ackd.2021.08.001_bib102","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000185335","article-title":"Acute renal failure after high-dose methotrexate therapy","volume":"51","author":"Thierry","year":"1989","journal-title":"Nephron"},{"issue":"2","key":"10.1053\/j.ackd.2021.08.001_bib103","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000188722","article-title":"A case of methotrexate-lnduced acute renal failure Successfully treated with plasma Perfusion and Sequential hemodialysis","volume":"71","author":"Kawabata","year":"1995","journal-title":"Nephron"},{"issue":"13","key":"10.1053\/j.ackd.2021.08.001_bib104","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.ejca.2009.04.033","article-title":"Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study","volume":"45","author":"Scagliotti","year":"2009","journal-title":"Eur J Cancer"},{"issue":"14","key":"10.1053\/j.ackd.2021.08.001_bib105","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.ackd.2021.08.001_bib106","first-page":"2677","article-title":"Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034","volume":"6","author":"McLeod","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1053\/j.ackd.2021.08.001_bib107","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40620-014-0117-5","article-title":"Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage","volume":"28","author":"Rombola","year":"2015","journal-title":"J Nephrol"},{"key":"10.1053\/j.ackd.2021.08.001_bib108","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lungcan.2020.05.022","article-title":"Cumulative pemetrexed dose increases the risk of nephrotoxicity","volume":"146","author":"de Rouw","year":"2020","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1053\/j.ackd.2021.08.001_bib109","doi-asserted-by":"crossref","first-page":"402","DOI":"10.5414\/CN107921","article-title":"Pemetrexed-induced acute kidney injury leading to chronic kidney disease","volume":"82","author":"Chauvet","year":"2014","journal-title":"Clin Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2021.08.001_bib110","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1053\/j.ajkd.2011.04.030","article-title":"Kidney tubular toxicity of maintenance pemetrexed therapy","volume":"58","author":"Glezerman","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1053\/j.ackd.2021.08.001_bib111","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3109\/0886022X.2010.501930","article-title":"Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed","volume":"32","author":"Stavroulopoulos","year":"2010","journal-title":"Ren Fail"},{"issue":"3","key":"10.1053\/j.ackd.2021.08.001_bib112","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1385\/MO:23:3:419","article-title":"Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer","volume":"23","author":"Vootukuru","year":"2006","journal-title":"Med Oncol"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib113","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1053\/j.ajkd.2016.04.016","article-title":"Pemetrexed-induced nephrogenic diabetes insipidus","volume":"68","author":"Fung","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib114","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00884-2018","article-title":"Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study","volume":"52","author":"Visser","year":"2018","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1053\/j.ackd.2021.08.001_bib115","doi-asserted-by":"crossref","first-page":"e0171066","DOI":"10.1371\/journal.pone.0171066","article-title":"Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: a retrospective cohort study","volume":"12","author":"Kawazoe","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib116","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00873232","article-title":"Phase II trial of gemcitabine (2, 2\u2032-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas","volume":"12","author":"Casper","year":"1994","journal-title":"Invest New Drugs"},{"issue":"12","key":"10.1053\/j.ackd.2021.08.001_bib117","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/cncr.20290","article-title":"Gemcitabine-associated thrombotic microangiopathy","volume":"100","author":"Humphreys","year":"2004","journal-title":"Cancer"},{"issue":"2","key":"10.1053\/j.ackd.2021.08.001_bib118","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00277-004-0938-8","article-title":"Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution","volume":"84","author":"M\u00fcller","year":"2005","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1053\/j.ackd.2021.08.001_bib119","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/bcp.13808","article-title":"Thrombotic microangiopathy associated with gemcitabine use: presentation and outcome in a national French retrospective cohort","volume":"85","author":"Daviet","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib120","first-page":"30","article-title":"Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review","volume":"5","author":"Ustwani","year":"2014","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib121","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12882-018-0812-x","article-title":"The use of eculizumab in gemcitabine induced thrombotic microangiopathy","volume":"19","author":"Krishnappa","year":"2018","journal-title":"BMC Nephrol"},{"issue":"7","key":"10.1053\/j.ackd.2021.08.001_bib122","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/adc.65.7.732","article-title":"Nephrotoxicity after ifosfamide","volume":"65","author":"Skinner","year":"1990","journal-title":"Arch Dis Child"},{"issue":"12","key":"10.1053\/j.ackd.2021.08.001_bib123","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1200\/JCO.1991.9.12.2177","article-title":"Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report","volume":"9","author":"Suarez","year":"1991","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib124","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/ckj\/sfz183","article-title":"Ifosfamide nephrotoxicity in adult patients","volume":"13","author":"Ensergueix","year":"2020","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib125","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1006\/taap.1994.1241","article-title":"Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney","volume":"129","author":"Zamlauskitucker","year":"1994","journal-title":"Toxicol Appl Pharmacol"},{"issue":"8","key":"10.1053\/j.ackd.2021.08.001_bib126","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1681\/ASN.V1281615","article-title":"Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide","volume":"12","author":"Dubourg","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ackd.2021.08.001_bib127","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.ejca.2012.03.009","article-title":"Long term renal toxicity of ifosfamide in adult patients\u20135 year data","volume":"48","author":"Farry","year":"2012","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1053\/j.ackd.2021.08.001_bib128","first-page":"1636","article-title":"Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study","volume":"82","author":"Skinner","year":"2000","journal-title":"Br J Cancer"},{"issue":"9027","key":"10.1053\/j.ackd.2021.08.001_bib129","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0140-6736(96)03480-0","article-title":"Risk factors for ifosfamide nephrotoxicity in children","volume":"348","author":"Skinner","year":"1996","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2021.08.001_bib130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.urology.2016.07.030","article-title":"Review of advances in uroprotective agents for cyclophosphamide-and ifosfamide-induced hemorrhagic cystitis","volume":"100","author":"Matz","year":"2017","journal-title":"Urology"},{"issue":"11","key":"10.1053\/j.ackd.2021.08.001_bib131","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1200\/JCO.1991.9.11.2016","article-title":"Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation","volume":"9","author":"Shepherd","year":"1991","journal-title":"J Clin Oncol"},{"issue":"45","key":"10.1053\/j.ackd.2021.08.001_bib132","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/BF00638623","article-title":"Managing a side effect: cyclophosphamide-induced hemorrhagic cystitis","volume":"45","author":"Arnold","year":"1958","journal-title":"Naturwiss Schaften"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib133","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/art.25061","article-title":"Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review","volume":"62","author":"Monach","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1053\/j.ackd.2021.08.001_bib134","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/gyno.1999.5680","article-title":"Hemorrhagic pyelitis, ureteritis, and cystitis secondary to cyclophosphamide: case report and review of the literature","volume":"76","author":"Wong","year":"2000","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1053\/j.ackd.2021.08.001_bib135","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0014-2964(81)90261-9","article-title":"Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention\u2014I: Experimental studies on the urotoxicity of alkylating compounds","volume":"17","author":"Brock","year":"1981","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib136","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/1097-0142(19830215)51:4<606::AID-CNCR2820510409>3.0.CO;2-S","article-title":"Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2, 2\u2032-dithio-bis-ethane sulfonate (dimesna)","volume":"51","author":"Habs","year":"1983","journal-title":"Cancer"},{"issue":"11","key":"10.1053\/j.ackd.2021.08.001_bib137","first-page":"1577","article-title":"Cyclophosphamide and urinary bladder toxicity","volume":"21","author":"Philips","year":"1961","journal-title":"Cancer Res"},{"issue":"5","key":"10.1053\/j.ackd.2021.08.001_bib138","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/01.ju.0000154344.80669.e3","article-title":"Peroxynitrite may be involved in bladder damage caused by cyclophosphamide in rats","volume":"173","author":"Korkmaz","year":"2005","journal-title":"J Urol"},{"issue":"6","key":"10.1053\/j.ackd.2021.08.001_bib139","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1097\/01.ju.0000085593.31396.d8","article-title":"Involvement of nitric oxide and hyperbaric oxygen in the pathogenesis of cyclophosphamide induced hemorrhagic cystitis in rats","volume":"170","author":"Korkmaz","year":"2003","journal-title":"J Urol"},{"issue":"11","key":"10.1053\/j.ackd.2021.08.001_bib140","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/FPC.0b013e328313aaa4","article-title":"Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin","volume":"18","author":"Ekhart","year":"2008","journal-title":"Pharmacogenet Genomics"},{"issue":"7","key":"10.1053\/j.ackd.2021.08.001_bib141","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1200\/JCO.1993.11.7.1306","article-title":"Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial","volume":"11","author":"Vose","year":"1993","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.ackd.2021.08.001_bib142","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0022-5347(17)39702-1","article-title":"Cyclophosphamide-induced hemorrhagic pyelitis and ureteritis associated with cystitis in marrow transplantation","volume":"144","author":"Efros","year":"1990","journal-title":"J Urol"},{"issue":"11","key":"10.1053\/j.ackd.2021.08.001_bib143","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/sj.bmt.1705139","article-title":"Polyoma BK virus and haemorrhagic cystitis in haematopoietic stem cell transplantation: a changing paradigm","volume":"36","author":"Leung","year":"2005","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"10.1053\/j.ackd.2021.08.001_bib144","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0022-5347(17)75787-4","article-title":"Cyclophosphamide induced hemorrhagic cystitis","volume":"137","author":"Stillwell","year":"1987","journal-title":"J Urol"},{"issue":"7","key":"10.1053\/j.ackd.2021.08.001_bib145","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","article-title":"Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin\u2019s lymphoma","volume":"87","author":"Travis","year":"1995","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib146","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2008.17.2627","article-title":"American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants","volume":"27","author":"Hensley","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.ackd.2021.08.001_bib147","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2165\/00003495-199142030-00006","article-title":"Ifosfamide\/mesna","volume":"42","author":"Dechant","year":"1991","journal-title":"Drugs"},{"key":"10.1053\/j.ackd.2021.08.001_bib148","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0305-7372(83)80005-X","article-title":"The development of mesna for regional detoxification","volume":"10","author":"Brock","year":"1983","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1053\/j.ackd.2021.08.001_bib149","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/archinte.1985.00360030196034","article-title":"Water intoxication following moderate-dose intravenous cyclophosphamide","volume":"145","author":"Bressler","year":"1985","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1053\/j.ackd.2021.08.001_bib150","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/bmt.2015.257","article-title":"Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity","volume":"51","author":"Garciaz","year":"2016","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"10.1053\/j.ackd.2021.08.001_bib151","first-page":"36","article-title":"Acquired gitelman syndrome secondary to bendamustine use","volume":"101","author":"Rogers","year":"2018","journal-title":"R Med J"},{"issue":"2","key":"10.1053\/j.ackd.2021.08.001_bib152","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1053\/j.ajkd.2016.07.037","article-title":"Bendamustine-induced nephrogenic diabetes insipidus in a patient with AL amyloidosis","volume":"69","author":"Uwumugambi","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib153","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.ajkd.2004.09.015","article-title":"Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation","volume":"45","author":"Leung","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib154","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/1097-0142(19850101)55:1<44::AID-CNCR2820550107>3.0.CO;2-B","article-title":"Syndrome of inappropriate antidiuretic hormone secretion. A complication of high-dose intravenous melphalan","volume":"55","author":"Greenbaum-Lefkoe","year":"1985","journal-title":"Cancer"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbcan.2017.01.004","article-title":"Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling","volume":"1868","author":"Nikolova","year":"2017","journal-title":"Biochim Biophys Acta (Bba)-reviews Cancer"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib156","doi-asserted-by":"crossref","first-page":"108","DOI":"10.7326\/0003-4819-79-1-108","article-title":"Pancreatic islet cell carcinoma: II. Results of therapy with streptozotocin in 52 patients","volume":"79","author":"Broder","year":"1973","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1053\/j.ackd.2021.08.001_bib157","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2004.05.210","article-title":"Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients","volume":"22","author":"Yovine","year":"2004","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.ackd.2021.08.001_bib158","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/1078155209352821","article-title":"Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma","volume":"16","author":"Pick","year":"2010","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"10.1053\/j.ackd.2021.08.001_bib159","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s10637-011-9662-0","article-title":"A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials","volume":"30","author":"Le Cesne","year":"2012","journal-title":"Invest New Drugs"},{"issue":"5","key":"10.1053\/j.ackd.2021.08.001_bib160","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/pbc.24869","article-title":"Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis","volume":"61","author":"Armstrong","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1053\/j.ackd.2021.08.001_bib161","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib162","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/ki.2013.408","article-title":"Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer","volume":"85","author":"Shavit","year":"2014","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ackd.2021.08.001_bib163","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1634\/theoncologist.2011-0422","article-title":"Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?","volume":"17","author":"Kwa","year":"2012","journal-title":"Oncologist"},{"issue":"2","key":"10.1053\/j.ackd.2021.08.001_bib164","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","article-title":"Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems","volume":"65","author":"Tacar","year":"2013","journal-title":"J Pharm Pharmacol"},{"issue":"25","key":"10.1053\/j.ackd.2021.08.001_bib165","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/092986709788803312","article-title":"Doxorubicin: the Good, the Bad and the Ugly effect","volume":"16","author":"Carvalho","year":"2009","journal-title":"Curr Med Chem"},{"issue":"5","key":"10.1053\/j.ackd.2021.08.001_bib166","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/ctrv.2000.0202","article-title":"Mitomycin C: a clinical update","volume":"27","author":"Bradner","year":"2001","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1053\/j.ackd.2021.08.001_bib167","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0272-6386(86)80112-3","article-title":"Nephrotoxicity induced by cancer chemotherapy with special Emphasis on cisplatin toxicity","volume":"8","author":"Ries","year":"1986","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ackd.2021.08.001_bib168","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib169","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/1097-0142(19850101)55:1<47::AID-CNCR2820550108>3.0.CO;2-#","article-title":"Renal complications of mitomycin C therapy with special reference to the total dose","volume":"55","author":"Valavaara","year":"1985","journal-title":"Cancer"},{"issue":"17","key":"10.1053\/j.ackd.2021.08.001_bib170","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.bmcl.2018.06.044","article-title":"Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead","volume":"28","author":"Martino","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib171","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/23993693211002216","article-title":"Cancer therapy-induced hyponatremia: a case-illustrated review","volume":"5","author":"Pelletier","year":"2021","journal-title":"J Onco-nephrology"},{"issue":"1","key":"10.1053\/j.ackd.2021.08.001_bib172","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7326\/0003-4819-101-1-41","article-title":"Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy","volume":"101","author":"Jackson","year":"1984","journal-title":"Ann Intern Med"},{"issue":"2-3","key":"10.1053\/j.ackd.2021.08.001_bib173","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/08860228909066955","article-title":"Hemolytic uremic syndrome following cisplatin, bleomycin, and vincristine chemotherapy","volume":"11","author":"Gardner","year":"1989","journal-title":"Ren Fail"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559521000756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559521000756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:04:31Z","timestamp":1761548671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559521000756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":172,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1548559521000756"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2021.08.001","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conventional Chemotherapy Nephrotoxicity","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2021.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}